
Merck & Co Inc
NYSE:MRK

US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
Retail
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
73.47
131.0275
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.

Intrinsic Value
The intrinsic value of one
MRK
stock under the Base Case scenario is
120.9159
USD.
Compared to the current market price of 79.4051 USD,
Merck & Co Inc
is
Undervalued by 34%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Merck & Co Inc
Historical valuation for MRK cannot be conducted due to limitations such as insufficient data or other constraints.
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
|
FR |
![]() |
Sanofi SA
PAR:SAN
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:

Heavily reliant on Keytruda’s continued success, Merck faces heightened risk if competitors launch effective immuno-oncology therapies or if pricing pressures intensify following patent expiration.
A weaker-than-expected pipeline, particularly in next-generation oncology and vaccines, raises concerns over Merck’s ability to sustain revenue growth after flagship products lose exclusivity.
Budgetary tightening and reimbursement restrictions in key markets could reduce patient access to Merck’s high-value therapies, pressuring margins and limiting overall sales growth.
Keytruda’s dominant position in the immuno-oncology market and ongoing label expansions are poised to drive strong, sustained revenue and strengthen Merck’s leadership in cancer treatments.
Gardasil’s robust demand, reinforced by global vaccination campaigns, provides Merck with a reliable, high-margin revenue stream that can buoy earnings even if other franchises face headwinds.
A well-funded R&D engine, coupled with strategic in-licensing and acquisitions in areas like oncology, cardiovascular, and vaccines, positions Merck to deliver new blockbuster therapies long term.

Revenue & Expenses Breakdown
Merck & Co Inc
Balance Sheet Decomposition
Merck & Co Inc
Current Assets | 35.5B |
Cash & Short-Term Investments | 9.2B |
Receivables | 11.6B |
Other Current Assets | 14.7B |
Non-Current Assets | 79.6B |
Long-Term Investments | 1.7B |
PP&E | 24.8B |
Intangibles | 37.4B |
Other Non-Current Assets | 15.6B |
Current Liabilities | 25.2B |
Accounts Payable | 3.8B |
Accrued Liabilities | 12.6B |
Other Current Liabilities | 8.8B |
Non-Current Liabilities | 41.6B |
Long-Term Debt | 33.5B |
Other Non-Current Liabilities | 8.1B |
Free Cash Flow Analysis
Merck & Co Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Merck & Co Inc
Revenue
|
63.9B
USD
|
Cost of Revenue
|
-14B
USD
|
Gross Profit
|
50B
USD
|
Operating Expenses
|
-28.3B
USD
|
Operating Income
|
21.6B
USD
|
Other Expenses
|
-4.2B
USD
|
Net Income
|
17.4B
USD
|
MRK Profitability Score
Profitability Due Diligence
Merck & Co Inc's profitability score is 68/100. The higher the profitability score, the more profitable the company is.

Score
Merck & Co Inc's profitability score is 68/100. The higher the profitability score, the more profitable the company is.
MRK Solvency Score
Solvency Due Diligence
Merck & Co Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.

Score
Merck & Co Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MRK Price Targets Summary
Merck & Co Inc
According to Wall Street analysts, the average 1-year price target for
MRK
is 104.8334 USD
with a low forecast of 82.82 USD and a high forecast of 153.3 USD.
Dividends
Current shareholder yield for MRK is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
MRK
stock under the Base Case scenario is
120.9159
USD.
Compared to the current market price of 79.4051 USD,
Merck & Co Inc
is
Undervalued by 34%.